top of page

Stifel's Paul Matteis covers earnings season and recent clinical data in biotech on Analyst Thursdays

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, Alector, Neurocrine, and more.



Comentários


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page